Fivetran Launches Hybrid Deployment, Enabling Enterprises to Run Pipelines in Any Environment on a Unified Platform
18.9.2024 10:00:00 CEST | Business Wire | Press release
Hybrid Deployment offers a secure, flexible solution for seamless data movement across environments
Fivetran, the global leader in data movement, today announced Hybrid Deployment, a new solution that allows customers to securely run data pipelines within their own environment from the Fivetran managed platform, providing a single control plane to manage all data sources, whether they are cloud-based SaaS apps or legacy databases with data that needs to be tightly controlled and managed for regulatory or compliance purposes. With the industry’s most comprehensive selection of connectors, destinations and features, Fivetran empowers enterprises to centralize data efficiently, reliably and securely, while supporting governance and compliance requirements and benefiting from 24/7 support.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240918100338/en/
Introducing Fivetran’s Hybrid Deployment: A fully managed service that meets the highest enterprise security standards. (Graphic: Business Wire)
Enterprises with sensitive data or in regulated industries often struggle to build data-driven practices. Seamless data access is critical for boosting efficiency, enabling AI-powered analytics and producing reliable data products. Centralizing data can lead to complex, costly systems that burden engineering teams. Traditional SaaS tools often lack the needed control and security, forcing organizations into more cumbersome solutions. DIY or self-hosted solutions often fail to scale effectively, especially as data priorities evolve in the age of AI, resulting in inefficiencies and an urgent need for modernization. Fivetran’s Hybrid Deployment simplifies this by enabling businesses to securely centralize their data and prepare it for AI and machine learning, all while maintaining control over sensitive information.
"Introducing a hybrid cloud deployment model to the Fivetran platform opens up entirely new possibilities for businesses of all sizes," said George Fraser, Fivetran CEO. "Businesses no longer have to choose between managed automation and data control. They can now securely move data from all their critical sources—like Salesforce, Workday, Oracle, SAP, other cloud and on-premises databases and ERPs—into a data warehouse or data lake, all while keeping that data under their own control. This is especially valuable for industries like healthcare and life sciences and financial services, where secure, compliant and reliable data is critical."
How Hybrid Deployment works
Hybrid Deployment keeps sensitive data within the customer’s environment while taking advantage of Fivetran’s management and monitoring tools. A lightweight local connector securely moves the data, while Fivetran’s user-friendly interface makes configuration and monitoring simple, all from a single control plane.
"Fivetran's new hybrid deployment option is a game-changer. Now customers can easily centralize all their data, regardless of security or compliance requirements, given the ability to separate the control and data plane,” said Vinay Kumar Katta, Managing Delivery Architect, Capgemini. “Customers will appreciate Fivetran's best-in-class platform that offers the flexibility to choose how and where their pipelines run. We're excited to advance our partnership with Fivetran and help more enterprises modernize their data infrastructure."
The separate control and data plane architecture ensures data never leaves the customer’s secure environment, giving them ultimate control over how their data is moved while still benefiting from Fivetran’s managed platform. This solution automates and centralizes the data movement process, while also giving enterprises the benefits of:
- Full visibility: Monitor all pipelines from a single interface.
- Data security: Control access, mask sensitive data and track movement to ensure compliance.
- Compatibility across environments: Works across AWS, Microsoft Azure, Google Cloud, and on-premises environments.
- Simple setup: Quick installation with no complex maintenance required.
- Flexibility: Scale and customize pipelines with integrations for APIs and tools like Terraform.
- Cost management: Track usage and control budgets with detailed reporting tools.
"phData is excited about Fivetran's new Hybrid Deployment option, which allows our customers in regulated industries like healthcare, life sciences and financial services to scale the configuration and ingestion of highly sensitive datasets on self-managed infrastructure," said Troy Fokken, Chief Architect at phData. "This approach streamlines the data pipeline processes, as customers don't need to self-host software or build DIY pipelines to securely move data from source systems to destination."
As government regulations like GDPR, HIPAA and CCPA continue to tighten, and new ones emerge, enterprises are increasingly focused on ensuring their data practices meet strict security and compliance standards. Recent breaches in healthcare and financial services have highlighted the risks of exposing sensitive information and compromising critical systems. DIY or self-managed pipelines can introduce vulnerabilities, especially as teams must frequently make updates in order to meet rapidly changing data schema, which increases the risk of errors that can lead to data breaches. Fivetran’s Hybrid Deployment mitigates these risks by providing a managed solution that runs within the customer’s secure environment, ensuring compliance while eliminating common points of failure.
“The simplicity of management is the best value of Hybrid Deployment,” said Ajay Bidani, Data and Insights Manager at Powell Industries. “I know the status of our pipelines and can launch and manage cloud-based and on-premises pipelines directly from one platform. Given our history with on-premises applications, I can say that pipelines going down and requiring restart was quite cumbersome, but Hybrid Deployment has been considerably different. I can realize the ease of monitoring and maintaining pipelines with immediacy. The ability to quickly stand up Hybrid Deployment for on-premises data movement, while managing it from a straightforward and familiar cloud-based control plane, is a great value add.”
Reducing complexity for engineering teams
Hybrid Deployment reduces manual setup and maintenance, allowing engineering teams to focus on building data-driven solutions. Fivetran handles the heavy lifting, helping businesses extract value from their data without worrying about brittle DIY infrastructure. A recent report by IDC found that enterprises can realize an average annual productivity gain of $1.5 million by transitioning to Fivetran’s managed data movement solution.
Fivetran’s data integration platform can handle high-volume change data capture from databases and offers 600+ pre-built connectors for a range of SaaS applications, events, files, ERPs, data warehouses and data lakes. The Fivetran platform replicates data with minimal impact on source systems, low latency and high throughput, making it the trusted choice for over 6,300 customers globally. With the richest technical feature set of any data ingestion tool, Fivetran meets the widest range of data integration use cases.
To learn more, visit the Fivetran blog or explore images and assets in the Fivetran newsroom. You can also start your free Hybrid Deployment trial today at Fivetran.com.
About Fivetran
Fivetran, the global leader in data movement, helps customers use their data to power everything from AI applications and ML models, to predictive analytics and operational workloads. The Fivetran platform reliably and securely centralizes data from hundreds of SaaS applications and databases into any cloud destination — whether deployed on-premises, in the cloud or in a hybrid environment. Thousands of global brands, including Autodesk, Condé Nast, JetBlue and Morgan Stanley, trust Fivetran to move their most valuable data assets to fuel analytics, drive operational efficiencies and power innovation. For more info, visit fivetran.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240918100338/en/
Contacts
Matias Cavallin
Matias Cavallin
323-715-0020
matias.cavallin@fivetran.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom